Browse > Article
http://dx.doi.org/10.3904/kjim.2016.282

Use of hypnotics and the risk of or mortality from heart disease: a meta-analysis of observational studies  

Kim, Young-Hyo (Department of Family Medicine, Myongji Hospital)
Kim, Hong-Bae (Department of Family Medicine, Myongji Hospital)
Kim, Do-Hyoung (Department of Family Medicine, Myongji Hospital)
Kim, Ja-Young (Department of Family Medicine, Myongji Hospital)
Shin, Hyun-Young (Department of Family Medicine, Myongji Hospital)
Publication Information
The Korean journal of internal medicine / v.33, no.4, 2018 , pp. 727-736 More about this Journal
Abstract
Background/Aims: Some observational epidemiologic studies have reported conflicting results on the relationship between hypnotics use and the risk of developing and/or dying from heart disease. We investigated these associations using a meta-analysis of available literatures. Methods: We searched the databases PubMed and EMBASE, along with the bibliographies of relevant articles to find additional publications in February 2016. Results: Of 495 articles satisfying our initial criteria, two case-control studies and six cohort studies met our inclusion criteria and were included in the final analyses. Compared with never having used any kind of hypnotics, the odds ratio for overall use was 0.84 for risk of or mortality from heart disease (95% confidence interval, 0.79 to 0.89) in a random-effects meta-analysis of all eight studies. With respect to the geographical region, use of hypnotics was associated with a decreased risk or mortality of heart disease in Asia but not in Western countries. Among various types of sleep medications, zolpidem showed a decreased risk (-29%) of developing or dying from heart disease, but benzodiazepines were related with an increased risk (80%) of or mortality from heart disease. Conclusions: The current meta-analysis of observational epidemiological studies suggested an evidence of association between hypnotics use and a decreased risk of heart disease.
Keywords
Hypnotics; Heart disease; Observational study; Meta-analysis;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Inagaki T, Miyaoka T, Tsuji S, Inami Y, Nishida A, Horiguchi J. Adverse reactions to zolpidem: case reports and a review of the literature. Prim Care Companion J Clin Psychiatry 2010;12:e1-e8.
2 Mailliet F, Galloux P, Poisson D. Comparative effects of melatonin, zolpidem and diazepam on sleep, body temperature, blood pressure and heart rate measured by radiotelemetry in Wistar rats. Psychopharmacology (Berl) 2001;156:417-426.   DOI
3 Zhou X, Zhang Y, Chen J, Xu W. Use of non-benzodiazepine hypnotics is associated with decreased risk of coronary artery disease. Intern Med 2012;51:829-832.   DOI
4 Mallon L, Broman JE, Hetta J. Sleep complaints predict coronary artery disease mortality in males: a 12-year follow-up study of a middle-aged Swedish population. J Intern Med 2002;251:207-216.   DOI
5 Belleville G. Mortality hazard associated with anxiolytic and hypnotic drug use in the National Population Health Survey. Can J Psychiatry 2010;55:558-567.   DOI
6 Rod NH, Andersen I, Prescott E. Psychosocial risk factors and heart failure hospitalization: a prospective cohort study. Am J Epidemiol 2011;174:672-680.   DOI
7 Jaussent I, Ancelin ML, Berr C, et al. Hypnotics and mortality in an elderly general population: a 12-year prospective study. BMC Med 2013;11:212.   DOI
8 Lan TY, Zeng YF, Tang GJ, et al. The use of hypnotics and mortality: a population-based retrospective cohort study. PLoS One 2015;10:e0145271.   DOI
9 Sofi F, Cesari F, Casini A, Macchi C, Abbate R, Gensini GF. Insomnia and risk of cardiovascular disease: a meta-analysis. Eur J Prev Cardiol 2014;21:57-64.   DOI
10 Vogelzangs N, Seldenrijk A, Beekman AT, van Hout HP, de Jonge P, Penninx BW. Cardiovascular disease in persons with depressive and anxiety disorders. J Affect Disord 2010;125:241-248.   DOI
11 Roest AM, Martens EJ, de Jonge P, Denollet J. Anxiety and risk of incident coronary heart disease: a meta-analysis. J Am Coll Cardiol 2010;56:38-46.   DOI
12 Vermeeren A. Residual effects of hypnotics: epidemiology and clinical implications. CNS Drugs 2004;18:297-328.   DOI
13 Morin CM, LeBlanc M, Daley M, Gregoire JP, Merette C. Epidemiology of insomnia: prevalence, self-help treatments, consultations, and determinants of help-seeking behaviors. Sleep Med 2006;7:123-130.   DOI
14 Mellinger GD, Balter MB, Uhlenhuth EH. Insomnia and its treatment: prevalence and correlates. Arch Gen Psychiatry 1985;42:225-232.   DOI
15 Ohayon MM, Caulet M, Priest RG, Guilleminault C. Psychotropic medication consumption patterns in the UK general population. J Clin Epidemiol 1998;51:273-283.   DOI
16 Alvarenga JM, Loyola Filho AI, Firmo JO, Lima-Costa MF, Uchoa E. Prevalence and sociodemographic characteristics associated with benzodiazepines use among community dwelling older adults: the Bambui Health and Aging Study (BHAS). Rev Bras Psiquiatr 2008;30:7-11.
17 Sanna E, Busonero F, Talani G, et al. Comparison of the effects of zaleplon, zolpidem, and triazolam at various GABA(A) receptor subtypes. Eur J Pharmacol 2002;451:103-110.   DOI
18 Weissinger J. NDA 19-908 ambien pharmacology memos & exclusivity summary [Internet]. Silver Spring (US): U.S. Food and Drug Administration, c1992 [cited 2017 Jul 21]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019908_S000_PHARM_MEMOS&EXCLUSIVITY_SUMMARY.pdf.
19 Jehle J, Ficker E, Wan X, et al. Mechanisms of zolpideminduced long QT syndrome: acute inhibition of recombinant hERG K(+) channels and action potential prolongation in human cardiomyocytes derived from induced pluripotent stem cells. Br J Pharmacol 2013;168:1215-1229.   DOI
20 Kim DH, Lee JT, Lee IK, Ha JH. Comparative anticancer effects of flavonoids and diazepam in cultured cancer cells. Biol Pharm Bull 2008;31:255-259.   DOI
21 Mallon L, Broman JE, Hetta J. Is usage of hypnotics associated with mortality? Sleep Med 2009;10:279-286.   DOI
22 Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-1558.   DOI
23 DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188.   DOI
24 Merlo J, Hedblad B, Ogren M, et al. Increased risk of ischaemic heart disease mortality in elderly men using anxiolytics-hypnotics and analgesics: results of the 10-year follow-up of the prospective population study "Men born in 1914", Malmo, Sweden. Eur J Clin Pharmacol 1996;49:261-265.   DOI
25 Lapane KL, Zierler S, Lasater TM, Barbour MM, Carleton R, Hume AL. Is the use of psychotropic drugs associated with increased risk of ischemic heart disease? Epidemiology 1995;6:376-381.   DOI
26 Huang MP, Radadia K, Macone BW, Auerbach SH, Datta S. Effects of eszopiclone and zolpidem on sleep-wake behavior, anxiety-like behavior and contextual memory in rats. Behav Brain Res 2010;210:54-66.   DOI
27 Bild DE, Detrano R, Peterson D, et al. Ethnic differences in coronary calcification: the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation 2005;111:1313-1320.   DOI
28 Price JF, Fowkes FG. Risk factors and the sex differential in coronary artery disease. Epidemiology 1997;8:584-591.   DOI
29 Gensini GF, Comeglio M, Colella A. Classical risk factors and emerging elements in the risk profile for coronary artery disease. Eur Heart J 1998;19 Suppl A:A53-A61.
30 Virmani R, Farb A, Burke AP. Risk factors in the pathogenesis of coronary artery disease. Compr Ther 1998;24:519-529.
31 Muzet A, Johnson LC, Spinweber CL. Benzodiazepine hypnotics increase heart rate during sleep. Sleep 1982;5:256-261.   DOI
32 Hojer J. Management of benzodiazepine overdose. CNS Drugs 1994;2:7-17.   DOI
33 Ickowicz S, Hayashi K, Dong H, et al. Benzodiazepine use as an independent risk factor for HIV infection in a Canadian setting. Drug Alcohol Depend 2015;155:190-194.   DOI
34 Kingery JR, Alfred Y, Smart LR, et al. Short-term and long-term cardiovascular risk, metabolic syndrome and HIV in Tanzania. Heart 2016;102:1200-1205.   DOI
35 Bach P, Walton G, Hayashi K, et al. Benzodiazepine use and hepatitis C seroconversion in a cohort of persons who inject drugs. Am J Public Health 2016;106:1067-1072.   DOI
36 Domont F, Cacoub P. Chronic hepatitis C virus infection, a new cardiovascular risk factor? Liver Int 2016;36:621-627.   DOI
37 deLemos AS, Wolfe ML, Long CJ, Sivapackianathan R, Rader DJ. Identification of genetic variants in endothelial lipase in persons with elevated high-density lipoprotein cholesterol. Circulation 2002;106:1321-1326.   DOI
38 Ancoli-Israel S, Roth T. Characteristics of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. I. Sleep 1999;22 Suppl 2:S347-S353.
39 Colten HR, Altevogt BM. Sleep Disorders and Sleep Deprivation: An Unmet Public Health Problem. Washington (DC): National Academies Press, 2006.
40 Nomura K, Yamaoka K, Nakao M, Yano E. Impact of insomnia on individual health dissatisfaction in Japan, South Korea, and Taiwan. Sleep 2005;28:1328-1332.   DOI